Thomas Dehmel
Overview
Explore the profile of Thomas Dehmel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graf J, Leussink V, Dehmel T, Ringelstein M, Goebels N, Adams O, et al.
Ann Clin Transl Neurol
. 2018 Jan;
4(12):909-914.
PMID: 29296620
The increasing number of potent treatments for multiple sclerosis warrants screening for infections. To investigate the prevalence of infections in two independent German patient cohorts with multiple sclerosis/neuromyelitis optica spectrum...
2.
Weber A, Zimmermann C, Mausberg A, Dehmel T, Kieseier B, Hartung H, et al.
Infect Immun
. 2016 Feb;
84(5):1413-1423.
PMID: 26902726
Infections with Pseudomonas aeruginosa may cause many different diseases. The spectrum of such infections in general includes inflammation and bacterial sepsis. Hospital-acquired pneumonia, naturally resistant to a wide range of...
3.
Grutzke B, Hucke S, Gross C, Herold M, Posevitz-Fejfar A, Wildemann B, et al.
Ann Clin Transl Neurol
. 2015 Mar;
2(2):119-30.
PMID: 25750917
Objective: To evaluate the influence of Fingolimod treatment on B-cell subset composition and function in multiple sclerosis patients and its potential clinical relevance. Methods: Subset composition and cytokine production of...
4.
Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, et al.
Ann Clin Transl Neurol
. 2015 Feb;
2(1):43-55.
PMID: 25642434
Objective: To identify microRNAs (miRNAs) regulated by anti-α4 integrin monoclonal antibody therapy (natalizumab) in the peripheral blood of patients with relapsing-remitting (RR) multiple sclerosis (MS) and to confirm their role...
5.
Kim S, Hyun J, Jeong I, Joung A, Yeon J, Dehmel T, et al.
J Neurol
. 2015 Jan;
262(3):696-700.
PMID: 25559683
Rituximab, a chimeric monoclonal anti-CD20 antibody, has been proposed to be effective for neuromyelitis optica spectrum disorder (NMOSD). A concern for developing progressive multifocal leukoencephalopathy (PML), which is caused by...
6.
Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg A, Geldern G, et al.
Mult Scler
. 2014 Nov;
21(8):1036-44.
PMID: 25392339
Background: Natalizumab for multiple sclerosis (MS) increases the risk of progressive multifocal leukoencephalopathy (PML). Objective: We aimed to assess the effect of natalizumab on cellular composition and functional B cell...
7.
Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, et al.
Neurology
. 2014 Nov;
83(23):2153-7.
PMID: 25361781
Objective: To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remitting multiple sclerosis (RRMS). Methods:...
8.
Warnke C, Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, et al.
Ann Neurol
. 2014 Apr;
76(6):792-801.
PMID: 24729444
Objective: Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), can occur in patients receiving natalizumab for multiple sclerosis (MS). JCV detection by quantitative polymerase chain reaction (qPCR) in cerebrospinal...
9.
Stettner M, Lohmann B, Wolffram K, Weinberger J, Dehmel T, Hartung H, et al.
J Neuroinflammation
. 2014 Apr;
11:63.
PMID: 24678820
Background: Pro-inflammatory cytokines are known to have deleterious effects on Schwann cells (SCs). Interleukin 17 (IL-17) is a potent pro-inflammatory cytokine that exhibits relevant effects during inflammation in the peripheral...
10.
Warnke C, Mausberg A, Stettner M, Dehmel T, Nekrich L, Meyer Zu Horste G, et al.
Neurology
. 2013 Sep;
81(16):1400-8.
PMID: 24049136
Objective: To assess changes in the T-cell receptor (TCR) repertoire in peripheral venous blood and CSF of patients with multiple sclerosis (MS) treated with natalizumab and the potential implication for...